Maryland-Based Biopharmaceutical Company Solaxa Inc. Receives Significant Funding from TEDCO’s Venture Funds July 25, 2024 TEDCO, Maryland’s economic engine for technology companies, has announced a substantial investment of $500,000 in [….]
Creative Bio-Peptides, Inc., an emerging drug development company focused on the development of leading-edge multi-chemokine antagonist therapeutic peptides for neuroinflammatory/neurodegenerative conditions, has been awarded $5.8M in non-dilutive funding from three NIH agencies.
Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced the completion of two lease agreements that will more than quadruple the company’s manufacturing capacity for its lead asset, CNM-Au8®, a gold nanocrystal suspension.
Clene Nanomedicine, one of Maryland’s Future 2020 companies, closed a merger with Tottenham Acquisition I Limited that provided the company with a slot on the Nasdaq Exchange and $3.19 million that will be used to advance the company’s gold nanocrystal-based treatment for neurodegenerative diseases.
